X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Interest Coverage Ratio of 10.84 for Q4 2025, up 30.06% on a YoY basis from 8.34 in Q4 2024, and up 11.05% quarter-over-quarter from 12.19 in Q3 2025.
X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Interest Coverage Ratio for 9 years, with the latest figure at 10.84 in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio rose 30.06% year-over-year to 10.84; the trailing twelve-month figure through Dec 2025 stood at 9.79 (down 135.78% YoY), and the FY2025 full-year result was 9.79, down 135.78% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 10.84, up from 12.19 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 32.68 in Q2 2024, with the low at 31.41 in Q4 2021.
- Historically, Interest Coverage Ratio has averaged 15.81 across 5 years, with a median of 19.85 in 2022.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio jumped 245.37% — and 2025, when it sank 135.97%.
- X4 Pharmaceuticals' Interest Coverage Ratio stood at 31.41 in 2021, then advanced by 28.82% to 22.36 in 2022, then soared by 40.24% to 13.36 in 2023, then slipped by 16.02% to 15.5 in 2024, then surged by 30.06% to 10.84 in 2025.
- The last three Interest Coverage Ratio figures came in at 10.84 (Q4 2025), 12.19 (Q3 2025), and 11.75 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -258.33 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 11.79 |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -10.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.84 |
| Sep 30, 2025 | -12.19 |
| Jun 30, 2025 | -11.75 |
| Mar 31, 2025 | -4.29 |
| Dec 31, 2024 | -15.50 |
| Sep 30, 2024 | -14.29 |
| Jun 30, 2024 | 32.68 |
| Mar 31, 2024 | -19.90 |
| Dec 31, 2023 | -13.36 |
| Sep 30, 2023 | -16.65 |
| Jun 30, 2023 | -22.48 |
| Mar 31, 2023 | -26.42 |
| Dec 31, 2022 | -22.36 |
| Sep 30, 2022 | -19.80 |
| Jun 30, 2022 | -22.41 |
| Mar 31, 2022 | -23.29 |
| Dec 31, 2021 | -31.41 |
| Sep 30, 2021 | -20.78 |
| Jun 30, 2021 | -20.99 |
| Mar 31, 2021 | -20.13 |